IP Journal of Urology, Nephrology and Hepatology Science

---

Doxycycline and Ursodeoxycholic acid in the treatment of AA amyloidosis

Full Text PDF Share on Facebook Share on Twitter

---

Case Report

Author Details : Shanmuganathan Velu, Niranjan Raja*, Arul Rajagopalan, Jegan Arunachalam, Arun Prasath

Volume : 4, Issue : 2, Year : 2021

Article Page : 63-66

Suggest article by email

---

Abstract

Amyloidoses are disorders of protein folding and metabolism in which insoluble fibrils are deposited in body organs, causing organ dysfunction. Till date, more than 36 different proteins have been identified as amyloidogenic; and at least 17 of them can cause systemic disease. Out of these, AA amyloidosis is probably the most common type of amyloidosis worldwide, as most reported cases from developing countries are associated with underlying infections. Renal involvement is common (nearly 95 %) in patients with AA amyloidosis, patients present with proteinuria and/or renal failure. The optimal treatment strategy of AA amyloidosis includes control of the underlying inflammatory disease and thereby complete suppression of SAA production. Several drugs have shown anti-amyloid properties in recent times. Recently doxycycline (a tetracycline antibiotic) and ursodeoxycholic acid (UDCA) have been shown to have an anti-amyloid effect through different mechanisms.

Keywords: AA amyloidosis, Proteinuria, Doxycycline, Ursodeoxycholic acid.

How to cite : Velu S , Raja N , Rajagopalan A , Arunachalam J , Prasath A , Doxycycline and Ursodeoxycholic acid in the treatment of AA amyloidosis. J Urol Nephrol Hepatol Sci 2021;4(2):63-66

Copyright © 2021 by author(s) and J Urol Nephrol Hepatol Sci. This is an Open Access article distributed under the terms of the Creative Commons Attribution 4.0 International License (creativecommons.org)